Skip to main content
ACXP logo

ACXP · Acurx Pharmaceuticals, Inc.

Track ACXP — free
$1.12 +0.09 (+8.74%)
Market Cap
$6.24M
Shares
6.06M
Volume · Nov 19 131.97K Avg daily vol (3M) 97.86K

Price & Indicators

 

Key stats

Close
$1.03
Open
$1.03
Day range
$1.03–1.11
52-week closing range
$0.94–6.63
Average volume, 30 days
105K
Short interest
98K · 1.6% of shares · 1.6 days
Short volume, last session
30%
Last earnings
Nov 12, 2026
Latest filing
10-Q · Nov 12
Price history
Jun 2021 to Nov 2026

Up next

Mar 12, 2027 Est · unconfirmed · in 16 wks

Latest documents

2026
Nov 13
Current report 8-K Events of Nov 12
Joseph C. Scodari retires from board, stays as advisor

Joseph C. Scodari will retire from Acurx Pharmaceuticals, Inc.’s Board effective November 13, 2026, then continue as a corporate advisor. His departure stems from no disagreement over operations, policies or practices.

Director or officer change, or executive pay
3 source passages
On November 12, 2026, Joseph C. Scodari, a member of the Board of Directors (the “Board”) of Acurx Pharmaceuticals, Inc. (the “Company”) since 2021, provided the Company with notice of his intention to retire from the Board, effective November 13, 2026. Mr. Scodari’s decision did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Following his retirement from the Board, Mr. Scodari has agreed to continue to serve the Company as a corporate advisor. Open the document at this passage
Nov 12
Earnings call
Pathfinder enrollment began as cash reached $9.7 million

Acurx Pharmaceuticals began enrolling patients on September 29th in the 20-patient Pathfinder trial for multiply-recurrent CDI. Cash totaled $9.7 million at September 30, 2026, and net loss was $2.6 million, or 49 cents per diluted share, for the three months ended September 30, 2026.

3 source passages
Second, on September 29th of this year, we began enrolling patients in the Pathfinder 20-patient ground-breaking clinical trial in multiply-recurrent CDI. The company ended the quarter with cash totaling $9.7 million. The company reported a net loss of $2.6 million, or 49 cents per diluted share, for the three months ended September 30, 2026. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Ibezapolstat recurrent-CDI trial enrolls first patient ahead of schedule

Acurx Pharmaceuticals says its ibezapolstat recurrent-CDI pilot enrolled its first patient in the third quarter, ahead of schedule, with up to 20 patients planned. It reported a $6.5 million nine-month net loss and $9.7 million cash as of September 30, 2026.

Net loss $2.58M Diluted EPS -$0.49
Read from the MD&A section
4 source passages
On March 9, 2026, we announced a new clinical development initiative to expand the ibezapolstat program into recurrent C. difficile infection (rCDI). The initiative includes an open label pilot trial in multiply recurrent CDI that will enroll up to 20 patients who have experienced at least 3 CDI episodes within the past 12 months. Trial start-up activities began in the second quarter, and first patient enrollment was originally expected in the fourth quarter of this year. The first patient was enrolled in the third quarter, ahead of schedule. Net loss was $6.5 million for the nine months ended September 30, 2026 and $6.4 million for the nine months ended September 30, 2025, an increase of $0.1 million, due to the reasons stated above. As of September 30, 2026, we had working capital of $7.3 million, consisting primarily of $9.7 million of cash and $0.6 million of prepaid expenses, offset by approximately $3.0 million of accounts payable and accrued expenses. Open the document at this passage
Oct 29
Current report 8-K
Board cuts stockholder meeting quorum to one-third of voting power

The board adopted an amendment to the bylaws effective October 29, 2026, reducing the stockholder meeting quorum to one-third of the voting power outstanding and entitled to vote, from a majority previously.

Charter or bylaw amendment, or fiscal year change
2 source passages
On October 29, 2026, the Board of Directors of Acurx Pharmaceuticals, Inc. (the “Company”) approved and adopted, effective as of that date, an amendment (the “Amendment”) to the Company’s Bylaws (the “Bylaws”). The Amendment reduces the quorum at all meetings of the Company’s stockholders for the transaction of business, except as otherwise required by law or by the Company’s Certificate of Incorporation, as amended, or Bylaws, to one-third (33⅓%) of the voting power of the stock outstanding and entitled to vote at the meeting, present in person, present by remote communication, if applicable, or represented by proxy. Open the document at this passage
Oct 16
Investor event
2026 Annual Meeting of Stockholders

Acurx Pharmaceuticals' 2026 Annual Meeting elected David Luci and Dr. Jack Dean as Class II Directors and ratified CohnResnick LLP as independent auditor for fiscal year ending December 31, 2026, with approximately 52.8 percent quorum present.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$8.10M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$9.65M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+226.9%
Year over year · more shares
Price change (1Y)
-74.3%
Trailing year
Short interest
1.6%
Latest settlement · 1.6 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −45%
below
Price vs 50-day avg −13%
below
RSI (14) 45
neutral
MACD trend Positive
52-week position 2%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −10%
trailing
6-month return −47%
trailing
YTD return −59%
this year
Relative strength −41%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.61% of shares out · ▲ +7.5% MoM · 1.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
19 holders — mid 3-yr range
Squeeze score 51
elevated · 0–100
Fundamentals
Excellent
EPS growth +70%
Y/Y
Balance sheet $7.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 161%
annualized · 1-yr
Max drawdown −86%
past year
ATR 8.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−45% Bearish
Price vs 50-day avg
−13% Bearish
RSI (14)
45 Neutral
MACD trend
Positive Bullish
52-week position
2% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.61% of shares out · ▲ +7.5% MoM · 1.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
19 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 2% Range high $7
vs 200-day avg -45% vs 50-day avg -13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ACXP
Acurx Pharmaceuticals, Inc.
this stock
$6.24M -58.6% — — 1.6%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
19
% held
3.0%
Net QoQ
+60.2K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Rising
Shares short
97.6K
Days to cover
1.6d
Change
+6.8K sh
View
Short Volume
Short vol %
30%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
951
Value
$1.0K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
65.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-8.0M
EPS diluted
$-5.32
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 13, 2026
This year
17

Joseph C. Scodari will retire from Acurx Pharmaceuticals, Inc.’s Board effective November 13, 2026, then continue as a corporate advisor. His departure stems from no disagreement over operations, policies or practices.

View
Exempt Offerings
Offering
$4.6M
Filed
Apr 29, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Acurx Pharmaceuticals, Inc. Annou…
Published
Apr 16, 2026
View

Performance

5D 20D 120D MTD YTD
ACXP +4.6% -9.7% -46.6% -1.0% -58.6%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +10.0% -3.4% -41.0% +4.3% -63.6%
Key facts CIK 1736243 CUSIP 00510M203 13F (30d) 20 filings 19 filers Visit website Investor relations